Electronic cigarette vapour increases virulence and inflammatory potential of respiratory pathogens.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
18 Dec 2019
Historique:
received: 01 04 2019
accepted: 04 10 2019
entrez: 19 12 2019
pubmed: 19 12 2019
medline: 2 6 2020
Statut: epublish

Résumé

Bacteria have been extensively implicated in the development of smoking related diseases, such as COPD, by either direct infection or bacteria-mediated inflammation. In response to the health risks associated with tobacco exposure, the use of electronic cigarettes (e-cigs) has increased. This study compared the effect of e-cig vapour (ECV) and cigarette smoke (CSE) on the virulence and inflammatory potential of key lung pathogens (Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa). Biofilm formation, virulence in the Galleria mellonella infection model, antibiotic susceptibility and IL-8/TNF-α production in A549 cells, were compared between bacteria exposed to ECV, CSE and non-exposed bacteria. Statistically significant increases in biofilm and cytokine secretion were observed following bacterial exposure to either ECV or CSE, compared to non-exposed bacteria; the effect of exposure to ECV on bacterial phenotype and virulence was comparable, and in some cases greater, than that observed following CSE exposure. Treatment of A549 cells with cell signaling pathway inhibitors prior to infection, did not suggest that alternative signaling pathways were being activated following exposure of bacteria to either ECV or CSE. These findings therefore suggest that ECV and CSE can induce changes in phenotype and virulence of key lung pathogens, which may increase bacterial persistence and inflammatory potential.

Identifiants

pubmed: 31847850
doi: 10.1186/s12931-019-1206-8
pii: 10.1186/s12931-019-1206-8
pmc: PMC6918581
doi:

Substances chimiques

CXCL8 protein, human 0
E-Cigarette Vapor 0
Inflammation Mediators 0
Interleukin-8 0
Smoke 0
TNF protein, human 0
Tumor Necrosis Factor-alpha 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

267

Références

Lancet. 2007 Sep 1;370(9589):765-73
pubmed: 17765526
APMIS. 2007 Aug;115(8):891-9
pubmed: 17696944
PLoS One. 2011 Feb 22;6(2):e16384
pubmed: 21364979
Infect Immun. 2012 Nov;80(11):3804-11
pubmed: 22890993
BMC Microbiol. 2014 Mar 12;14:61
pubmed: 24618025
J Bacteriol. 2000 Jul;182(13):3843-5
pubmed: 10851003
J Hyg (Lond). 1938 Nov;38(6):732-49
pubmed: 20475467
J Mol Med (Berl). 2016 Jun;94(6):667-79
pubmed: 26804311
N Engl J Med. 2019 Sep 6;:null
pubmed: 31491072
Tob Control. 2013 Jan;22(1):19-23
pubmed: 22034071
Respir Res. 2016 Jul 26;17(1):94
pubmed: 27460220
Appl Environ Microbiol. 2014 Dec;80(23):7212-8
pubmed: 25217021
Am J Respir Cell Mol Biol. 2016 Oct;55(4):586-601
pubmed: 27253086
PLoS One. 2015 Feb 04;10(2):e0116861
pubmed: 25651083
Am J Med. 2015 Jul;128(7):674-81
pubmed: 25731134
Expert Rev Respir Med. 2013 Jun;7(3):245-57
pubmed: 23734647
PLoS One. 2010 May 04;5(5):e9323
pubmed: 20454607
Eur Respir J. 2017 Apr 12;49(4):
pubmed: 28404649
BMJ. 2015 Apr 19;350:h2083
pubmed: 25896797
Cochrane Database Syst Rev. 2016 Sep 14;9:CD010216
pubmed: 27622384
Otolaryngol Head Neck Surg. 2012 Nov;147(5):876-84
pubmed: 22597576
Chest. 2019 Jan;155(1):88-93
pubmed: 30359612
Am J Respir Crit Care Med. 2018 Jul 1;198(1):67-76
pubmed: 29481290
J Vis Exp. 2013 Nov 22;(81):e50964
pubmed: 24299965
Front Pediatr. 2017 Feb 15;5:19
pubmed: 28261574
Eur Respir J. 2013 May;41(5):1058-67
pubmed: 22878876
Eur Respir J. 2013 Feb;41(2):392-5
pubmed: 22743667
Nicotine Tob Res. 2015 Feb;17(2):142-9
pubmed: 25239957
Am J Respir Crit Care Med. 2001 Aug 1;164(3):339-40
pubmed: 11500330
Toxicol In Vitro. 2014 Aug;28(5):999-1005
pubmed: 24809892
Am J Physiol Lung Cell Mol Physiol. 2019 Jan 1;316(1):L94-L104
pubmed: 30358437
Virulence. 2010 Nov-Dec;1(6):475-82
pubmed: 21178491
EBioMedicine. 2015 Sep 26;2(11):1686-96
pubmed: 26870795
Am J Physiol Lung Cell Mol Physiol. 2015 Dec 15;309(12):L1398-409
pubmed: 26408554
Nat Rev Immunol. 2002 May;2(5):372-7
pubmed: 12033743
Int J Occup Med Environ Health. 2017 May 8;30(3):329-344
pubmed: 28481369
Eur Respir J. 2012 Feb;39(2):467-77
pubmed: 21737564
Eur Respir J. 2019 Jan 31;53(2):null
pubmed: 30464018
PLoS One. 2012;7(3):e32924
pubmed: 22412951
Infect Immun. 2013 Oct;81(10):3552-65
pubmed: 23836821
Thorax. 2016 Sep;71(9):795-803
pubmed: 27146202
Am J Physiol Lung Cell Mol Physiol. 2015 Jul 15;309(2):L175-87
pubmed: 25979079
PLoS One. 2011 Jan 06;6(1):e15700
pubmed: 21253587
Chest. 2008 Aug;134(2):394-401
pubmed: 18682458
PLoS One. 2015 Feb 06;10(2):e0116732
pubmed: 25658421
FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):153-7
pubmed: 12381467
Infect Immun. 2015 Jun;83(6):2443-52
pubmed: 25824841
PLoS One. 2016 Oct 13;11(10):e0164038
pubmed: 27736944
Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L470-L486
pubmed: 30604630
Eur Respir J. 2017 May 1;49(5):
pubmed: 28461294
Biomed Res Int. 2014;2014:976347
pubmed: 25013815
Clin Exp Allergy. 1999 Jun;29 Suppl 2:90-5
pubmed: 10421830
Lancet Respir Med. 2016 Feb;4(2):116-28
pubmed: 26776875
N Engl J Med. 2008 Nov 27;359(22):2355-65
pubmed: 19038881

Auteurs

Deirdre F Gilpin (DF)

Halo Research Group, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, BT9 7BL, UK. d.f.gilpin@qub.ac.uk.

Katie-Ann McGown (KA)

Halo Research Group, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, BT9 7BL, UK.

Kevin Gallagher (K)

Halo Research Group, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, BT9 7BL, UK.

Jose Bengoechea (J)

Centre for Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, BT9 7BL, UK.

Amy Dumigan (A)

Centre for Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, BT9 7BL, UK.

Gisli Einarsson (G)

Halo Research Group, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, BT9 7BL, UK.

J Stuart Elborn (JS)

Centre for Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, BT9 7BL, UK.

Michael M Tunney (MM)

Halo Research Group, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, Northern Ireland, BT9 7BL, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH